BeOne Medicines (ONC) Jefferies London Healthcare Conference 2024 summary

Strategic vision and recent achievements

• Achieved over $1 billion in Q3 revenue and two consecutive quarters of positive non-GAAP operating income, with cash flow positivity supported by working capital.

• Brukinza became the market leader in first- and second-line CLL, with five hematology approvals and a robust pipeline including BCL2 and degrader assets.

• Nine new potential medicines entered the clinic this year, including eight in oncology and one degrader in INI, demonstrating rapid clinical development.

• Announced a name change to BeOne Medicines and re-domiciling from the Cayman Islands to Switzerland, aligning with a major oncology hub.

• Opened an $800 million biologics manufacturing facility in Princeton to support U.S. supply for biologics and ADCs.

Global commercial expansion and financial outlook

• Over 60% of revenue comes from the U.S. (50%) and Europe (10%), with Europe growing 217% year-over-year and further launches planned globally.

• Early-stage launches in markets like Brazil and Korea, with Japan yet to launch, signal ongoing globalization and competitive positioning.

• Operating leverage is improving through top-line growth, gross margin gains, and productivity investments, especially in manufacturing.

• Continued investment in R&D and commercial scaling, balancing growth with profitability and sustainability.

CLL franchise and clinical pipeline insights

• Brukinza demonstrated superior efficacy over Imbruvica in head-to-head trials, driving rapid adoption in CLL.

• Fixed duration therapies and combination regimens are under evaluation, with BCL2 (sonrotoclax) and degrader assets positioned for future franchise growth.

• Degrader shows promise in relapse settings, handling various mutations and potentially moving up in combination therapies.

• At ASH, 21 abstracts will be presented, including updated phase II data for sonrotoclax/Brukinza and long-term follow-up for zanubrutinib.